Skip to main content
. 2023 Jun 20;83(19):3252–3263. doi: 10.1158/0008-5472.CAN-23-0282

Figure 6.

Figure 6. Overview of ongoing KURRENT-HN tipifarnib–alpelisib dose escalation study and partial response (PR) of first patient enrolled in current dose cohort. CT of a patient with PIK3CA-mutant metastatic HNSCC at baseline and after five cycles of tipifarnib and alpelisib. Target lesions (red circles) are in the hilar lymph node and right upper lobe of the lungs. Patient experienced a partial response and remains on study at time of data cut (September 2022).

Overview of ongoing KURRENT-HN tipifarnib–alpelisib dose escalation study and partial response (PR) of first patient enrolled in current dose cohort. CT of a patient with PIK3CA-mutant metastatic HNSCC at baseline and after five cycles of tipifarnib and alpelisib. Target lesions (red circles) are in the hilar lymph node and right upper lobe of the lungs. Patient experienced a partial response and remains on study at time of data cut (September 2022).